



**HAL**  
open science

## Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study

Maxens Decavèle, Antoine Parrot, Michaël Duruisseaux, Martine Antoine, Anne Fajac, Audrey Milon, Marie-France F Carette, Anthony Canellas, Aude Gibelin, Alexandre Elabbadi, et al.

### ► To cite this version:

Maxens Decavèle, Antoine Parrot, Michaël Duruisseaux, Martine Antoine, Anne Fajac, et al.. Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study. *Journal of Thoracic Disease*, 2022, 14 (8), pp.2812 - 2825. 10.21037/jtd-22-12 . hal-04728534

**HAL Id: hal-04728534**

**<https://hal.science/hal-04728534v1>**

Submitted on 9 Oct 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



# Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study

Maxens Decavèle<sup>1,2,3^</sup>, Antoine Parrot<sup>4</sup>, Michaël Duruisseaux<sup>5,6</sup>, Martine Antoine<sup>7</sup>, Anne Fajac<sup>7</sup>, Audrey Milon<sup>8</sup>, Marie-France Carette<sup>8</sup>, Anthony Canellas<sup>4</sup>, Aude Gibelin<sup>1</sup>, Alexandre Elabbadi<sup>1</sup>, Marie Wislez<sup>9,10</sup>, Jacques Cadranel<sup>4</sup>, Muriel Fartoukh<sup>1</sup>

<sup>1</sup>Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France; <sup>2</sup>Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France; <sup>3</sup>Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Pitié-Salpêtrière, Service de Médecine Intensive et Réanimation (R3S), Paris, France; <sup>4</sup>Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France; <sup>5</sup>Department of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, France; <sup>6</sup>Cancer Research Center of Lyon, Inserm 1052, CNRS 5286, Oncopharmacology Team, Lyon, France; <sup>7</sup>Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Département d'Anatomie et cytologie pathologiques, Plateforme d'oncologie, Pathologie et biologie moléculaire, Paris, France; <sup>8</sup>Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon Service de Radiologie, Hôpital Tenon, Paris, France; <sup>9</sup>Université de Paris, Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Team Inflammation, Complement, and Cancer, Paris, France; <sup>10</sup>Oncology Thoracic Unit Pulmonology Department, AP-HP, Hôpital Cochin, Paris, France

**Contributions:** (I) Conception and design: M Decavèle, A Parrot, M Duruisseaux, MF Carette, M Wislez, J Cadranel, M Fartoukh; (II) Administrative support: M Decavèle, A Parrot, J Cadranel, M Fartoukh; (III) Provision of study materials or patients: M Decavèle, A Parrot, M Antoine, A Fajac, A Milon, MF Carette, A Gibelin, A Elabbadi, M Wislez, J Cadranel, M Fartoukh; (IV) Collection and assembly of data: M Decavèle, A Parrot, M Duruisseaux, A Gibelin, A Elabbadi, M Wislez, J Cadranel, M Fartoukh; (V) Data analysis and interpretation: M Decavèle, A Parrot, M Duruisseaux, M Antoine, A Fajac, A Milon, MF Carette, A Canellas, J Cadranel, M Fartoukh; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Dr. Maxens Decavèle, MD. Groupe Hospitalier Universitaire APHP-Sorbonne Université, Service de Médecine Intensive Réanimation, Hôpital Tenon, 4 rue de la Chine 75020 Paris cedex 20, France. Email: maxens.decavele@aphp.fr.

**Background:** The absence of diagnosis of acute respiratory distress syndrome (ARDS) concerns 20% of cancer patients and is associated with poorer outcomes. Diffuse pneumonic-type adenocarcinoma (P-ADC) is part of these difficult-to-diagnose ARDS, but only limited data are available regarding critically ill patients with diffuse P-ADC. We sought to describe the diagnosis process and the prognosis of P-ADC related ARDS patients admitted to the intensive care unit (ICU).

**Methods:** Single-center observational case series study. All consecutive patients admitted to the ICU over a two-decade period presenting with (I) histologically or cytologically proven adenocarcinoma of the lung and (II) ARDS according to Berlin definition were included. Clinical, biological, radiological and cytological features of P-ADC were collected to identify diagnostic clues. Multivariate logistic regression analyses were performed to assess factors associated with ICU and hospital mortality.

**Results:** Among the 24 patients included [70 (61–75) years old, 17 (71%) males], the cancer diagnosis was performed during the ICU stay in 19 (79%), and 17 (71%) required mechanical ventilation. The time between the first symptoms and the diagnosis of P-ADC was 210 days (92–246 days). A non-resolving pneumonia after 2 (2 to 3) antibiotics lines observed in 23 (96%) patients with a 34 mg/L (19 to 75 mg/L) plasma C-reactive protein level at ICU admission. Progressive dyspnea, bronchorrhea, salty expectoration,

<sup>^</sup> ORCID: 0000-0003-3552-5053.

fissural bulging and compressed bronchi and vessels were present in 100%, 83%, 69%, 57% and 43% of cases. Cytological examination of sputum or broncho-alveolar lavage provided a 75% diagnostic yield. The ICU and hospital mortality rates were 25% and 63%, respectively. The time (in days) between first symptoms and diagnosis [odds ratio (OR) 1.02, 95% confidence interval (95% CI): 1.00–1.03, P=0.046] and the Simplified Acute Physiology Score II (OR 1.16, 95% CI: 1.01–1.33, P=0.040) were independently associated with ICU mortality.

**Conclusions:** Non-resolving pneumonia after several antibiotics lines without inflammatory syndrome, associated with progressive dyspnea, salty bronchorrhea, and lobar swelling (i.e., fissural bulging, compressed bronchi and vessels) were suggestive of P-ADC. Delayed diagnosis of diffuse P-ADC seemed an independent prognostic predictor and disease timely recognition may contribute to prognosis improvement.

**Keywords:** Intensive care unit (ICU); acute respiratory distress syndrome (ARDS); pneumonic-type adenocarcinoma (P-ADC); broncho-alveolar carcinoma; lung cancer

Submitted Jan 05, 2022. Accepted for publication Jun 01, 2022.

doi: 10.21037/jtd-22-12

View this article at: <https://dx.doi.org/10.21037/jtd-22-12>

## Introduction

Acute respiratory failure (ARF) is the leading cause of intensive care unit (ICU) admission in cancer patients (1). Despite recent advances in diagnostic investigations, the cause of ARF remains undetermined in up to 20% of cancer patients with ARF (2,3), even in patients meeting acute respiratory distress syndrome (ARDS) criteria (4). In these patients, failure to identify the cause of ARF is independently associated with increased mortality (3,5) and a delayed diagnosis and subsequent delayed treatment may also have unfavorable impact on prognosis (6).

Malignant lung involvement represents recognized causes of ARDS mimickers (7,8), accounting for 20% of ARDS without common risk factors (8) and up to 30% of unexplained pulmonary infiltrates in cancer patients (9). Likely to occur at the time of the malignancy diagnosis (1), the severity of malignant lung infiltration may range from scarce infiltrate to life-threatening ARDS especially in case delayed diagnosis (10).

Pneumonic-type adenocarcinoma (P-ADC) encompasses heterogeneous mechanisms of cancer-related lung injury that may also progress to malignant ARDS, especially in case of tumor spread through air spaces (diffuse P-ADC) (11). Its association with hypoxemia, chest pain, and sometimes fever makes the diagnosis challenging, mimicking infectious pneumonia (12), and may induce delayed diagnosis and management. Moreover, its treatment and prognosis may be substantially different from those of ARDS with common risk factors. Indeed, in comparison with ARDS of

common causes, malignant ARDS has been demonstrated with high risk of ICU mortality (up to 96%) (8) and diffuse P-ADC may benefit from early administration of anti-cancer treatments. Thus, a better understanding of the diagnostic features and the determinants of the outcome of P-ADC patients presenting with ARDS are of major clinical importance, since timely diagnosis and appropriate management may improve the prognosis (13). However, no data are available regarding this type of malignant ARDS when ICU admission is required.

Here, we sought to describe the profile and prognosis of patients admitted to the ICU with diffuse P-ADC related ARDS. The primary objective was to provide the diagnostic clues from the clinical suspicion to the pathological confirmation, based on our clinical experience. The secondary objective was to assess the determinants of ICU and in-hospital mortality. We hypothesized that the diagnosis was delayed in most patients, which was associated with a worse prognosis. We present the following article in accordance with the STROBE reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-22-12/rc>).

## Methods

### *Study design and setting*

This observational case series study was conducted from January 1998 to January 2018 in a 20-bed French medical ICU, part of the thoracic oncology department of Tenon

University Hospital, Paris, France, a medical and surgical reference center. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the French Intensive Care Society Institutional Review Board (CE SRLF 21-23) and informed consent was taken from the patients or their relatives.

### **Patient selection**

Patients were included if they met the three following criteria: (I) admission to the ICU during the study period; (II) histologically or cytologically proven adenocarcinoma of the lung according to the 2011 IASLC/ATS/ERS classification of lung adenocarcinoma (14) and the 2015 WHO classification of lung tumors (11); and (III) presenting with ARDS on ICU admission. The ARDS was defined by (I) a new or worsening respiratory symptoms over the last seven days; (II) bilateral pneumonia-like opacities on chest radiograph or computed tomography scan; (III) the absence of suspected cardiogenic pulmonary edema and of common causes of ARDS; and (IV) a PaO<sub>2</sub>/FiO<sub>2</sub> ratio ≤300 mmHg (15). A positive end-expiratory pressure level of at least 5 cmH<sub>2</sub>O was not necessary for inclusion.

Patients with a previous history of other thoracic or extra thoracic adenocarcinoma, presenting with ARDS of common causes, or under the age of 18 years were excluded. Concomitant bacterial pneumonia was not an exclusion criterion.

### **Data collection**

#### **Characteristics of the patients**

Age, gender, performance status (PS) during the week preceding ICU admission, clinically important weight loss, defined by a >5% loss of usual body weight over the last six months, smoking history and main comorbidities using the Charlson Comorbidity Index were collected for each patient. Symptoms and physical signs on respiratory examination (e.g., dyspnea, cough, bronchorrhea, chest pain) were collected. Physiological variables such as body temperature, respiratory rate, heart rate, systolic arterial blood pressure and Glasgow coma scale were also recorded, as well as main laboratory variables (e.g., arterial blood gas, leukocyte count, C-reactive protein, serum creatinine). Severity on admission was assessed by the Simplified Acute Physiology Score (SAPS) II and the Sequential Organ Failure Assessment (SOFA). Advanced life support measures administered during the ICU stay

such as mechanical ventilation (MV) either invasive or non-invasive (NIV), High Flow Oxygen Therapy, vasopressors and renal replacement therapy were also collected. Finally, we recorded ICU- and hospital mortality.

#### **Oncological evaluation**


All histological (trans-bronchial biopsy, open-lung biopsy and autopsy) and cytological [sputum examination, bronchial aspirate, broncho-alveolar lavage (BAL)] samples were reviewed by experienced lung pathologist (M Antoine) and cytologist (A Fajac) and histological samples of patients admitted before 2011 were re-classified according to current classifications (11,14). For the BAL procedures we used 50 mL of room temperature, sterile 0.9% saline injected via handheld 50 mL syringe, this repeated 4 times to reach a total of 200 mL instilled in the lungs. The cancer diagnosis could be confirmed based on cytological analysis (e.g., BAL), only if at least one agglomerate of neoplastic cells forming typical cytological features of P-ADC was identified. Details on pathological definitions are available in the [Appendix 1](#). Patients were classified as already diagnosed or newly diagnosed P-ADC, depending on whether cancer had been diagnosed before ICU referral or during ICU stay. Molecular testing (i.e., cancer biomarkers) was also collected, when performed. Staging was recorded according to the current TNM Classification System for lung cancer (16). Finally, anticancer treatment (chemotherapy, high doses of corticosteroids) administered during the ICU stay was also collected.

#### **Radiological evaluation**

Radiologic characteristics were assessed by an independent radiologist expert (MF Carette). Main CT findings, including (I) normal attenuation, (II) ground-glass attenuation, (III) alveolar consolidation and (IV) crazy paving were quantitatively measured, using a CT-scan extent score (17). Briefly, each lung was divided in three zones, i.e., upper, middle, and lower. Then, the percentage of lung parenchymal surface represented by each pattern was estimated in each six zones (3 right, 3 left). Finally, the average score of the six lung zones was calculated (adding each zone score, divided by 6).

#### **Statistical analysis**

Continuous variables are expressed as median (0.25–0.75 interquartile range) and categorical variables are expressed as absolute and relative frequency (%). Each potential



**Figure 1** Flowchart. P-ADC, pneumonic-type adenocarcinoma; ICU, intensive care unit; ARDS, acute respiratory distress syndrome.

factor associated with ICU or hospital mortality was evaluated in a univariate model. Variables were compared with Mann-Whitney test for quantitative variables and chi-square test or Fisher exact test for qualitative variables. All tests were two-sided and P values <0.05 were considered statistically significant. Because of the small sample size, a maximum of three variables identified with a P value less than 0.20 in univariate analyses, and/or clinically relevant (including time between first symptoms and diagnosis—the tested hypothesis) were included in a multivariate logistic regression model. The final models were determined using a forward stepwise logistic regression. The Hosmer-Lemeshow Chi-square test was used to check the goodness-of-fit of the final model. Odds ratios (ORs) and their 95% confidence intervals (CI) were calculated for significant factors. Because SAPS II and SOFA scores are highly correlated, SOFA was not entered in the models. Missing data (less than 1%) were not imputed. Statistical analysis was performed with SPSS Base 21.0 statistical software package (SPSS Inc., Chicago, IL, USA).

## Results

The flowchart of the study is represented in the *Figure 1*. During the study period, 24 patients with P-ADC related ARDS were referred to our ICU and thus included. These admissions resulted in transfer from the respiratory wards (n=13; 54%), the emergency services (n=6; 25%) or other

ICUs (n=5; 21%).

### *Patient's characteristics*

All the patients had a confirmed diagnosis of adenocarcinoma, all TNM staged M1a. The diagnosis was based on the examination of histological samples in 16 (67%) patients (13 trans-bronchial biopsies, 2 open-lung biopsies and 1 lung resection specimen) divided in 9 invasive mucinous adenocarcinoma (IMA) and 7 lepidic predominant adenocarcinoma (LPA). For the eight (33%) remaining patient without histological specimen, the diagnosis of adenocarcinoma was based on cytological analysis of BAL. More details on pathological findings are available in *Table S1*. The main characteristics of the 24 patients are displayed in *Table 1* and *Table S2*. The diagnosis of cancer was established during the ICU stay in 19 (79%) patients, 1 (1 to 4) day after ICU admission. For the remaining 5 (21%) patients, the diagnosis was established prior to ICU admission, a median of 2 (0.5–4) months before admission.

### *Bedside diagnostic reasoning process: from the clinic-radiological suspicion to the quick cytological examination*

Main clinical, biological, radiological and cytological diagnostic features of the 24 patients are reported in *Table 2*. Eighteen (75%) had a smoking history (9 active smokers on ICU admission), with a cumulative consumption of 38 (15

**Table 1** Univariate analysis: factors associated with ICU mortality

Variables	All (n=24)	ICU mortality		P value
		Non-survivors (n=6)	Survivors (n=18)	
Age (years)	70 (61–75)	71 (67–77)	69 (60–75)	0.42
Gender (male), n (%)	17 (71)	4 (67)	13 (72)	1
Performance status 3–4, n (%)	9 (38)	2 (33)	7 (39)	1
Charlson comorbidity Index	6 (6–7)	6 (6–7)	6 (6–7)	0.99
Time from first symptoms to diagnosis (days)	210 (92–246)	234 (199–413)	155 (88–244)	0.047
Never received anticancer treatment*, n (%)	8 (33)	1 (17)	7 (39)	0.621
Severity assessment on ICU admission				0.04
SAPS II	41 (33–46)	48 (41–56)	36 (31–44)	0.094
SOFA score	3 (2–4)	4 (3–5)	2 (3–4)	–
ARDS severity, n (%)				0.06
Mild	6 (25)	2 (33)	4 (17)	
Moderate	5 (21)	2 (33)	3 (13)	
Severe	13 (54)	2 (33)	11 (45)	
Physiological variables on ICU admission				
Systolic blood pressure (mmHg)	129 (105–138)	125 (104–138)	131 (98–140)	0.86
Respiratory rate (cycles/min)	26 (24–30)	44 (34–48)	26 (23–28)	0.004
Heart rate (beats/min)	95 (88–114)	121 (111–129)	93 (85–107)	0.015
Temperature (°C)	37.5 (37.0–38.0)	37.6 (35.0–38.5)	37.5 (37.0–38.0)	0.782
Laboratory variables on ICU admission				
Leukocyte count (10 <sup>9</sup> /L)	12.3 (8.3–18.9)	12.5 (12.4–21.7)	11.4 (7.7–16.5)	0.121
C-reactive protein (mg/L) (on 21 patients)	34 (14–75)	58 (21–93)	32 (8–77)	0.512
Serum creatinine (µmol/L)	73 (66–93)	83 (63–147)	68 (65–93)	0.613
pH on arterial blood gas	7.43 (7.40–7.44)	7.37 (7.33–7.41)	7.44 (7.41–7.44)	0.01
Total BAL cell count (10 <sup>3</sup> /mL)	520 (240–900)	630 (160–840)	480 (255–952)	0.864
BAL neutrophil count (10 <sup>3</sup> /mL)	289 (79–614)	100 (64–563)	300 (54–782)	0.522
Radiological assessment on ICU admission				
Alveolar consolidation extent score	18 (12–43)	45 (13–58)	17 (12–28)	0.321
Normal lung extent score	48 (33–63)	37 (32–58)	52 (34–66)	0.513
Mediastinal lymphadenopathy, n (%)	3 (13)	2 (33)	1 (6)	0.133
Life supporting interventions, n (%)				
Mechanical ventilation	17 (71)	6 (100)	11 (61)	0.134
Non-invasive ventilation only	6 (25)	2 (33)	4 (22)	0.621
Vasopressors	4 (17)	2 (33)	2 (11)	0.257


Data are expressed as number and percentage [n (%)] for categorical variables, and median (interquartile interval) for continuous variables. \*, impossibility to dispense anticancer treatment at any time before, during or after ICU discharge. ICU, intensive care unit; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; ARDS, acute respiratory distress syndrome; BAL, broncho-alveolar lavage.



**Table 2** Specific clinical, biological and radiological features at the time of diagnosis of diffuse P-ADC

Variables	Values
Physical examination features, n (%)	
Dyspnea	24 (100)
Cough	20 (83)
Bronchorrhea	20 (83)
Salty expectoration on 13 patients	9 (69)
Crackles on auscultation	12 (50)
Significant weight loss	10 (42)
Fever	6 (25)
Chest pain	2 (8)
Hemoptysis	1 (4)
Clubbing	1 (4)
Biological features	
Leukocyte count ( $10^9/L$ )	12.3 (8.3–18.9)
C-reactive protein (mg/L) on 21 patients	34 (19–75)
Procalcitonin (ng/mL) on 15 patients	0.11 (0.09–0.94)
Serum lactate dehydrogenase (IU/L) on 21 patients	412 (285–645)
Arterial lactate (mmol/L)	1.2 (0.9–1.5)
Serum creatinine ( $\mu\text{mol/L}$ )	72 (65–92)
CT-scan radiological features (on 22 patients), n (%) / lung extent score (%)	
Alveolar consolidation	20 (95)/18 (12–43)
Ground-glass attenuation	19 (90)/10 (5–23)
Crazy paving	6 (29)/0 (0–2)
Bronchogram within consolidation	19 (90)
Fissural bulging	12 (57)
Compressed bronchus and vessel	9 (43)
Nodules/micronodules	12 (57)
<10	4 (33)
10–30	5 (42)
>30	3 (2)
Cyst/cavitation	8 (38)
Broncho-alveolar lavage features (on 22 patients), cell count ( $10^3/mL$ )/cell proportion (%)	
Total cell count	520 (240–900)
Neutrophil	289 (79–614)/64 (41–85)
Macrophage	141 (35–272)/20 (11–53)
Lymphocyte	11 (2–39)/4 (2–5)
Eosinophil	0 (0–11)/0 (0–2)

Data are expressed as number and percentage (n, %) for categorical variables, and median (interquartile interval) for continuous variables. P-ADC, pneumonic-type adenocarcinoma; CT, computed tomography.



**Figure 2** Main radiological features of ARDS related to diffuse P-ADC. (A) Intravenous contrast chest CT-scan shows ground glass attenuation predominant in the left lower lobe. (B) Intravenous contrast chest CT-scan shows bilateral and dense alveolar consolidation predominant in the left lung. (C) Parenchymal window: intravenous contrast chest CT-scan (MipPR: 10.0 mm) and (D) mediastinal window: injected chest CT-scan (MipPR: 10.0 mm) represent respectively the particular pattern of compressed bronchus (black arrow) and compressed pulmonary artery (black arrow) in a same patient, within a dense alveolar consolidation. We also note the presence of cavitation within the consolidation. ARDS, acute respiratory distress syndrome; P-ADC, pneumonic-type adenocarcinoma; CT, computed tomography.

to 48) pack-year.

### Clinical and biological features

At the time of diagnosis, all except one patient, presented with a clinical picture of a non-resolving pneumonia for which they had received 3 (2 to 3) antibiotic lines. Most patients presented with isolated respiratory failure. No patients had consciousness disorders. Vasopressors were required in 4 patients (all received also mechanical ventilation). Laboratory tests revealed a mild biological inflammatory syndrome.

### Radiological features


Alveolar consolidation and ground glass opacities were the two most frequent and extended radiological patterns (Figure 2), with several patterns coexisting in some patients. When present, fissural bulging was associated

in 75% of cases (9 of 12 patients) with a particular aspect of compressed bronchi and vessels (Figure 2). Mediastinal lymphadenopathy, pleural effusion, atelectasis, pulmonary embolism, interlobular thickening were less frequent and encountered in 3 (13%), 5 (24%), 4 (19%), 2 (10%) and 5 (24%) patients, respectively. Right lower lobe was the most affected lobe in 9 (43%) cases, followed by the left lower lobe in 7 (33%) cases. All these lesions resulted in a remaining lung spared area extent of 48% (33–63%). Repeated CT-scans over time were available in three patients, providing information on natural dynamic expansion of the disease (Figure S1).

### Cytological diagnostic challenge and expertise

Fiberoptic bronchoscopy found abundant clear secretions, mucosa inflammation and infiltration in 96%, 36% and 22% of cases, respectively. BAL showed a marked hyper





**Figure 3** Cytological features of P-ADC and confounding aspects with diffuse alveolar damage (with color): BAL samples (May-Grünwald Giemsa,  $\times 400$ ). (A-C) Different patients with agglomerated (morula) neoplastic cell (full arrows), forming typical cytological features of former broncho-alveolar carcinoma including clean background, absence of 3-dimensional clusters, neoplastic cells in flat sheets, orderly arrangement with round uniform nuclei, absence of nuclear overlap, absence of irregular nuclear membranes, fine granular chromatin, and nuclear grooves (18). (D-F) Cytological pitfall for the diagnosis of broncho-alveolar carcinoma because of its resemblance with cytological alveolar damage. Panel D (A.F courtesy) represents typical agglomerate of (desquamated) type 2 pneumocytes (dotted arrow) in a patient with alveolar damage (ARDS), which could be perceived as similar to the cytological finding in the Panel E (dotted arrow). However, Panel E corresponds to the BAL findings of a patient with P-ADC, as the presence of a typical neoplastic cell agglomerate of broncho-alveolar carcinoma (full arrow) can be observed in an enlarged view of the same picture (Panel F). P-ADC, pneumonic-type adenocarcinoma; BAL, broncho-alveolar lavage; ARDS, acute respiratory distress syndrome.

cellularity with neutrophil predominance, and confirmed the diagnosis in 17 of 23 patients (74% diagnostic yield), exhibiting agglomerated neoplastic cells (*Figure 3A-3C*). Interestingly, among the 3 patients transferred from other ICUs who underwent a BAL before being referred to the ICU, local cytologist reported the presence of desquamated type II pneumocytes in 2 cases, and wrongly concluded to the diagnostic of diffuse alveolar damage (DAD). Mere sputum cytological examination was performed in seven patients with bronchorrhea, and provided the diagnosis in 5 (71%) patients. More details on diagnostic procedure yields are available in [Table S3](#).

#### *ICU and in-hospital mortality*

ICU and in-hospital mortality rates were 25% and 63%,

respectively. Lengths of ICU and hospital stays were 9 (5 to 15) and 20 (9 to 39) days, respectively. Factors associated with ICU and hospital mortality, identified in univariate analysis, are shown [Table 1](#) and [Table S4](#) respectively.

Multivariate analysis of factors associated with ICU and hospital mortality are reported in [Table 3](#). More details about the variables selected, and the goodness-of-fit of the models are available in [Appendix 2](#). Neither the type of P-ADC (IMA or LPA) nor the mucinous feature was associated with ICU ( $P=0.68$  and  $P=0.46$  respectively) or in-hospital ( $P=0.68$  and  $P=0.46$  respectively) mortality.

#### *Sub-group of newly diagnosed patients*

Among the 19 newly diagnosed patients with P-ADC, 7

**Table 3** Multivariate analysis of factors associated with ICU and hospital mortality

Variables	Prediction model of ICU mortality		Prediction model of hospital mortality	
	OR (95% CI)	P value	OR (95% CI)	P value
Time between first symptoms and diagnosis (per day)	1.02 (1.00–1.03)	0.046	–	ns
SAPS II (per point)	1.16 (1.01–1.33)	0.040	–	–
Need for mechanical ventilation	–	ns	–	–
Heart rate (per point)	–	–	1.07 (1.00–1.15)	0.041
Impossibility to dispense chemotherapy at any time after diagnosis of the cancer	–	–	17.57 (1.19–254.48)	0.041

Dashes signifies that the variable has been proposed but excluded from the stepwise procedure. ICU, intensive care unit; OR, odds ratio; CI, confidence interval; SAPS, Simplified Acute Physiology Score; ns, no statistical significance.

(37%) received chemotherapy in the ICU in combination with high-dose steroid therapy (Table S2). The patients presenting with fever or biological inflammatory syndrome were more likely to not receive chemotherapy during their ICU stay (Table 4). The initiation of chemotherapy in the ICU was not associated with better ICU ( $P=1.0$ ) or in-hospital ( $P=0.382$ ) survival.

## Discussion

To the best of our knowledge, this is the first series of P-ADC related ARDS patients admitted to the ICU.

Main results can be summarized as follows: in patients admitted to the ICU with an ARDS related to diffuse P-ADC, (I) the clinical diagnosis was suspected by specific clinical, biological and radiological features after several lines of antimicrobial therapies and a prolonged care-pathway, (II) the diagnosis was finally confirmed by mere cytological examination of sputum or BAL in 75% of the cases, (III) the diagnosis was markedly delayed in most of cases, and (IV) this delay was independently associated with ICU mortality.

### *Clinical suspicion of P-ADC related ARDS: synthesis and comparison with existing data*

Faced with a clinical situation of ARDS mimickers or non-resolving pneumonia, the present study provides various elements suggestive of the diagnosis of P-ADC-related ARDS. Firstly, the high incidence of bronchorrhoea observed in P-ADC with ARDS, contrasting with the 5–10% incidence observed in P-ADC without ARDS presentation (19), is in line with the fact that bronchorrhoea

is a late manifestation more likely to be observed in advanced or delayed diagnosed diffuse disease (20). Secondly, the salty taste of the bronchorrhoea has been previously reported (21), and is highly specific to P-ADC related bronchorrhoea. It is explained by an increased trans-epithelial chloride secretion (22,23), and an excessive transudation of plasma products into the airways (21,23) resulting in a broncho-alveolar mucus osmolality similar to that of plasma (20). Thirdly, nodules, fissural bulging and narrowed bronchus within consolidation at CT-scan were particularly frequent. These three signs have been demonstrated as helpful in differentiating P-ADC from infectious pneumonia (24). The proportion of pseudocavitation observed in our study is also similar to that reported in P-ADC (25). Fourthly, the mild biological inflammatory syndrome observed in our study is in contrast with that expected in patients with infectious pneumonia and should also evoke P-ADC. Finally, the high diagnostic yield of cytological examination (sputum, bronchial aspirate or BAL,) in P-ADC has been reported in different series (26–28), and relies on the identification of agglomerated neoplastic cells (type II pneumocytes or Clara cells) with specific cytological features (18).

However, the identification of such agglomerated neoplastic cells conceals an important diagnostic pitfall. Indeed, diffuse alveolar damage, the pathological hallmark of ARDS, is also characterized by type II pneumocytes proliferation (29), that has been qualified as reactive (30), atypical (31) hyperplastic (32) or desquamated (33) type II pneumocytes. In some cases, and as illustrated in the Figure 3D–3F, these cells shed in agglomerates (30–32) with an increased nuclear-cytoplasmic ratio, nuclear membrane irregularities, and prominent nucleoli, thus resembling

**Table 4** Characteristics of patients with newly diagnosed P-ADC related ARDS (n=19), receiving or not chemotherapy in the ICU

Variables	Chemotherapy (n=7)	No chemotherapy (n=12)	P value
Gender (male), n (%)	4 (57)	10 (83)	0.352
Age (years)	72 (61–74)	72 (65–76)	0.316
Performance status 3–4, n (%)	1 (14)	6 (50)	0.171
Clinical, laboratory and radiological variables			
Significant weight loss, n (%)	1 (14)	6 (50)	0.174
Temperature (°C)	36.6 (35.9–37.0)	37.5 (37.4–38.4)	0.042
Presence of molecular alterations, n (%)	2 (25)	3 (38)	0.675
Normal lung extent score (%)	52 (37–53)	63 (2–68)	0.492
Serum level of C-reactive protein (mg/L)	8 (6–16)	39 (33–70)	0.007
Presence of bacteria in LRT sample*	1 (14)	4 (33)	0.604
Severity assessment			
SAPS II	36 (34–44)	39 (32–48)	1
SOFA score	4 (2–5)	3 (2–3)	0.445
Severity of the ARDS, n (%)			0.427
Mild	5 (71)	6 (50)	
Moderate	0 (0)	4 (33)	
Severe	2 (29)	2 (17)	
Life supporting interventions, n (%)			
Mechanical ventilation	5 (71)	7 (58)	0.662
Vasopressors	2 (29)	1 (8)	0.526
ICU mortality	1 (14)	2 (17)	1
Hospital mortality	3 (43)	8 (67)	0.381


Data are expressed as number and percentage (n, %) for categorical variables, and median (interquartile interval) for continuous variables. \*, at significant threshold:  $>10^4$  cfu/mL for broncho-alveolar lavage and  $>10^3$  cfu/mL for plugged telescopic catheter. P-ADC, pneumonic-type adenocarcinoma; ARDS, acute respiratory distress syndrome; LRT, lower respiratory tract; ICU, intensive care unit; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; Cfu, colony forming unit.

the cells of adenocarcinoma (32,34). For instance, several of our diffuse P-ADC patients had been misdiagnosed as “common” ARDS before ICU referral, highlighting the crucial cooperation between clinicians and cytologists in the diagnosis process. The *Figure 4* provides a pictured summary of these main diagnostic features that intensivists should know about diffuse P-ADC mimicking ARDS.

#### **Outcomes: comparison with existing data**

The 63% hospital mortality observed in our study seemed substantially higher than the 36% hospital mortality

observed in a cohort of 446 lung cancer patients requiring ICU admission for mixed medical and surgical reasons (35). However, this mortality bordered on the 54% hospital mortality of patients with lung cancer admitted for medical reasons (mostly acute respiratory failure) (36) and reached that observed in 1,004 cancer patients with ARDS criteria (64%) (4). In line with previous reports on cancers patients presenting with ARF (3,5,6,10) our results showed that the time between first symptoms and diagnostic was independently associated with ICU mortality even after adjustment on severity. Pragmatically, a subsequent timely initiated chemotherapy may explain this association. This



**Figure 4** Pictured summary of the study. Delayed diagnosis of diffuse P-ADC is associated with mortality. Timely recognition is crucial but challenging, mimicking infectious ARDS. P-ADC, pneumonic-type adenocarcinoma; BAL, broncho-alveolar lavage; ARDS, acute respiratory distress syndrome.

is striking information for clinical practice regarding the possibility of reducing this delay with a better recognition of the key disease features. The positive influence of chemotherapy maintenance after ICU discharge on survival observed in our study, and reported by others (35,36), may supports a substantial efficacy of chemotherapy in these patients. Thus in the area of promising new therapies (targeted therapy, immunotherapy) (26,37) and the high prevalence of genomic molecular alteration in these patients (26,27,38), especially Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (39) (33% of KRAS mutation in our study), delay the initiation of chemotherapy seems particularly unsuitable for these patients. Interestingly, the decision to not continue or initiate chemotherapy during the ICU stay was certainly influenced by the suspicion of infection in a patient (higher body temperature and C-reactive protein plasma levels in patients without chemotherapy during the ICU stay).

### Limitations

First, this was a retrospective study, which involves a potential bias in patients' selection or data collection, and the small number of subjects limited the performance (discrimination) and thus the interpretation of the multivariate analyses. However, the rarity of the disease remains a major obstacle to prospective or large sample-size studies, even with a multicenter design. Second, we did not compare P-ADC related ARDS patients with other type of ARDS with alveolar consolidation such as community-acquired pneumonia, since clinical, biological and radiological patterns of community acquired pneumonia are well documented. Third, we only considered patients admitted to the ICU. Patients who were not considered for ICU admission for any reason, such as an estimated poor prognosis or a poor performance status, were therefore not included in this analysis.



## Conclusions

A rigorous physical, biological, radiological examination should raise a strong suspicion of P-ADC in patients presenting with atypical ARDS. Close collaboration with cytologist is the cornerstone of the diagnosis confirmation. Besides improvement in timely diagnostic recognition, further studies are warranted to test the benefits of high dose corticosteroids and specific anticancer therapy in these patients.

## Acknowledgments

*Funding:* None.

## Footnote

*Reporting Checklist:* The authors have completed the STROBE reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-22-12/rc>

*Data Sharing Statement:* Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-22-12/dss>

*Peer Review File:* Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-22-12/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-22-12/coif>). Maxens Decavèle reports non-financial support from ISIS medical. Michaël Duruisseaux declares grants, personal fees and non-financial support from Roche, Novartis, Pfizer, Takeda, Abbvie, BMS, MSD, ASTRAZENECA, Amgen, Boehringer Ingelheim for participation to boards of experts, lectures, or congress. Marie Wislez reports grants from ASTRAZENECA, Lilly, Merck KgA, MERUS, GSK, AMGEN, Novartis, MSD, and personal fees from BMS, MSD, Boehringer, Roche, ASTRAZENECA and Novartis. The other authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the French Intensive Care Society Institutional Review Board (CE

SRLF 21-23). Informed consent was taken from the patients or their relatives.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Azoulay E, Mokart D, Kouatchet A, et al. Acute respiratory failure in immunocompromised adults. *Lancet Respir Med* 2019;7:173-86.
2. Azoulay E, Mokart D, Lambert J, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. *Am J Respir Crit Care Med* 2010;182:1038-46.
3. Contejean A, Lemiale V, Resche-Rigon M, et al. Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologique (Grrr-OH) study. *Ann Intensive Care* 2016;6:102.
4. Azoulay E, Lemiale V, Mokart D, et al. Acute respiratory distress syndrome in patients with malignancies. *Intensive Care Med* 2014;40:1106-14.
5. Azoulay E, Mokart D, Rabbat A, et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. *Crit Care Med* 2008;36:100-7.
6. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* 2015;112 Suppl 1:S92-107.
7. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. *N Engl J Med* 2017;377:562-72.
8. Gibelin A, Parrot A, Maitre B, et al. Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition. *Intensive Care Med* 2016;42:164-72.
9. Zihlif M, Khanchandani G, Ahmed HP, et al. Surgical lung biopsy in patients with hematological malignancy or hematopoietic stem cell transplantation and unexplained



- pulmonary infiltrates: improved outcome with specific diagnosis. *Am J Hematol* 2005;78:94-9.
10. Mokart D, Lambert J, Schnell D, et al. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. *Leuk Lymphoma* 2013;54:1724-9.
  11. Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. *J Thorac Oncol* 2015;10:1243-60.
  12. Li J, Yen A, Lin GY. Recurrent pneumonia, persistent cough, and dyspnea in a 41-year-old man. *Chest* 2012;142:1338-42.
  13. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. *Ann Thorac Surg* 2002;74:1640-6; discussion 1646-7.
  14. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. *Proc Am Thorac Soc* 2011;8:381-5.
  15. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012;307:2526-33.
  16. Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification. *Chest* 2017;151:193-203.
  17. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. *Am J Respir Crit Care Med* 2008;177:433-9.
  18. Otori NP, Santa Maria EL. Cytopathologic diagnosis of bronchioloalveolar carcinoma: does it correlate with the 1999 World Health Organization definition? *Am J Clin Pathol* 2004;122:44-50.
  19. Edgerton F, Rao U, Takita H, et al. Bronchio-alveolar carcinoma. A clinical overview and bibliography. *Oncology* 1981;38:269-73.
  20. Spiro SG, Lopez-Vidriero M-T, Charman J, et al. Bronchorrhoea in a case of alveolar cell carcinoma. *J Clin Pathol* 1975;28:60-5.
  21. Dwek JH, Charytan C, Stachura I, et al. Salt-wasting bronchorrhoea and its mechanisms. *Arch Intern Med* 1977;137:791-4.
  22. Popat N, Raghavan N, McIvor RA. Severe bronchorrhoea in a patient with bronchioloalveolar carcinoma. *Chest* 2012;141:513-4.
  23. Homma H, Kira S, Takahashi Y, et al. A case of alveolar cell carcinoma accompanied by fluid and electrolyte depletion through production of voluminous amounts of lung liquids. *Am Rev Respir Dis* 1975;111:857-62.
  24. Aquino SL, Chiles C, Halford P. Distinction of consolidative bronchioloalveolar carcinoma from pneumonia: do CT criteria work? *AJR Am J Roentgenol* 1998;171:359-63.
  25. Jung JI, Kim H, Park SH, et al. CT differentiation of pneumonic-type bronchioloalveolar cell carcinoma and infectious pneumonia. *Br J Radiol* 2001;74:490-4.
  26. Wei J, Tang D, Nie Y, et al. Clinical characteristics and prognosis of nonsurgically treated patients with pneumonic-type adenocarcinoma. *Medicine (Baltimore)* 2019;98:e15420.
  27. Zong Q, Zhu F, Wu S, et al. Advanced pneumonic type of lung adenocarcinoma: survival predictors and treatment efficacy of the tumor. *Tumori* 2021;107:216-25.
  28. Wislez M, Massiani MA, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. *Chest* 2003;123:1868-77.
  29. Poletti V, Casoni GL, Cancellieri A, et al. Diffuse alveolar damage. *Pathologica* 2010;102:453-63.
  30. Linssen KC, Jacobs JA, Poletti VE, et al. Reactive type II pneumocytes in bronchoalveolar lavage fluid. *Acta Cytol* 2004;48:497-504.
  31. Bonaccorsi A, Cancellieri A, Chilosi M, et al. Acute interstitial pneumonia: report of a series. *Eur Respir J* 2003;21:187-91.
  32. Stanley MW, Henry-Stanley MJ, Gajl-Peczalska KJ, et al. Hyperplasia of type II pneumocytes in acute lung injury. Cytologic findings of sequential bronchoalveolar lavage. *Am J Clin Pathol* 1992;97:669-77.
  33. Grigoriu B, Jacobs F, Beuzen F, et al. Bronchoalveolar lavage cytological alveolar damage in patients with severe pneumonia. *Crit Care* 2006;10:R2.
  34. Grotte D, Stanley MW, Swanson PE, et al. Reactive type II pneumocytes in bronchoalveolar lavage fluid from adult respiratory distress syndrome can be mistaken for cells of adenocarcinoma. *Diagn Cytopathol* 1990;6:317-22.
  35. Soares M, Toffart AC, Timsit JF, et al. Intensive care in patients with lung cancer: a multinational study. *Ann Oncol* 2014;25:1829-35.
  36. Roques S, Parrot A, Lavole A, et al. Six-month prognosis of patients with lung cancer admitted to the intensive care unit. *Intensive Care Med* 2009;35:2044-50.

37. Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. *Cancer Discov* 2020;10:54-71.
38. Liu J, Shen J, Yang C, et al. High incidence of EGFR mutations in pneumonic-type non-small cell lung cancer. *Medicine (Baltimore)* 2015;94:e540.
39. Chang JC, Offin M, Falcon C, et al. Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. *Clin Cancer Res* 2021;27:4066-76.

**Cite this article as:** Decavèle M, Parrot A, Duruisseaux M, Antoine M, Fajac A, Milon A, Carette MF, Canellas A, Gibelin A, Elabbadi A, Wislez M, Cadranel J, Fartoukh M. Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study. *J Thorac Dis* 2022;14(8):2812-2825. doi: 10.21037/jtd-22-12